Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related HTWR
Benzinga's Top Upgrades
Bank Of America Upgrades HeartWare; Downgrades EndoChoice, Tandem
Related MSFT
Amazon-Salesforce Deal Could Top $50 Billion In Investments (If Cloud Continues Its Rise)
Jefferies Keeps $40 Target On Microsoft Following Phone Restructuring
Microsoft: It's Time For Surface Phone (Seeking Alpha)

Analysts at Goldman Sachs downgraded Heartware International (NASDAQ: HTWR) from “neutral” to “sell.” The target price for Heartware International has been lowered from $94 to $73. Heartware's shares closed at $81.26 on Friday.

Analysts at Deutsche Bank downgraded Microsoft (NASDAQ: MSFT) from “buy” to “hold.” The target price for Microsoft is set to $42. Microsoft's shares closed at $39.21 on Friday.

Morgan Stanley downgraded Mindray Medical International (NYSE: MR) from “overweight” to “equal-weight.” The target price for Mindray Medical has been lowered from $44 to $37. Mindray Medical's shares closed at $33.08 on Friday.

Analysts at Credit Suisse downgraded Enbridge (NYSE: ENB) from “outperform” to “neutral.” Enbridge's shares closed at $46.60 on Friday.

Latest Ratings for HTWR

DateFirmActionFromTo
May 2016Leerink SwannMaintainsOutperform
Mar 2016Bank of AmericaUpgradesNeutralBuy
Feb 2016Northland SecuritiesMaintainsMarket Perform

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (HTWR + ENB)

View Comments and Join the Discussion!